Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives

A method of increasing the bioavailability of 5-ASA to the colon of a subject comprising administering to a subject in need thereof a therapeutically effective amount of a 5-aminosalicylate compound with food.

A method of delaying the transit of 5-ASA in the colon of a subject comprising, administering a therapeutically effective amount of a 5-aminosalicylate compound to a subject in need thereof with food.

A method for decreasing systemic level of 5-ASA in a subject comprising, administering to a subject in need thereof a therapeutically effective amount of a 5-aminosalicylate compound with food.

A method of decreasing the maximal plasma concentration (Cmax) of a 5-aminosalicylate compound in a subject comprising, administering to a subject in need thereof a therapeutically effective amount of a 5-aminosalicylate compound with food.

A method of delaying Tmax of a 5-aminosalicylate compound in a subject comprising, administering to a subject in need thereof a therapeutically effective amount of a 5-aminosalicylate compound with food.

A method of decreasing the extent of absorption (AUClast) of a 5-aminosalicylate compound in a subject comprising, administering to a subject in need thereof a therapeutically effective amount of a 5-aminosalicylate compound with food.

A method of increasing the systemic ratio of NASA to 5-ASA in a subject comprising, administering to a subject in need thereof a therapeutically effective amount of a 5-aminosalicylate compound with food.

A method of increasing the conversion of 5-ASA to NASA in a subject comprising, administering to a subject in need thereof a therapeutically effective amount of a 5-aminosalicylate compound with food.

A method of decreasing the rate and extent of absorption of an oral dosage form of balsalazide as measured by the drug concentration or metabolite thereof attained in the blood stream over time in a subject comprising, administering to the subject a therapeutically effective amount of balsalazide in a pharmaceutical composition with food.

A method of using balsalazide in the treatment of gastrointestinal disease comprising:

• informing a subject with a gastrointestinal disease that the administration of a therapeutically effective amount of balsalazide with food results in a decrease in at least one of Cmax, AUClast, or systemic adsorption of balsalazide compared to administration without food.

A method of using balsalazide in the treatment of gastrointestinal disorders comprising altering the oral bioavailability of balsalazide by:

• obtaining balsalazide from a container providing information that administration of balsalazide with food increases the bioavailability of balsalazide or a metabolite thereof to the colon of the subject compared to administration without food, and ingesting the balsalazide with food.

A method of using balsalazide in the treatment of gastrointestinal disorders comprising:

• administering to a subject in need of treatment a therapeutically effective amount of balsalazide, with food, wherein the administration of the balsalazide with food results in a decrease in at least one of Cmax and AUClast of balsalazide as compared to administration of balsalazide in a fasted state;
• and informing the subject that the administration of a therapeutically effective amount of balsalazide in a pharmaceutical composition with food results in one or more of a decrease in at least one of Cmax and AUClast of balsalazide compared to administration in a fasted state.

A method of inhibiting the growth of a bacterial species in a human subject, comprising:

• administering to a human subject having a bacterial infection or overgrowth a pharmaceutically acceptable composition containing a 5-aminosalicylate compound in a dose effective to inhibit the growth of a bacterial species in the human subject with food.